The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around four in every 10 patients treated with these drugs, suggests a pooled data analysis of ...

Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

"This medication — which is a drug that inhibits ... In addition to acute pain, suzetrigine may also be a solution for neuropathic (nerve) pain, depending on the results of further studies ...

Platinum-based or taxane chemotherapy drugs appear to pose the greatest risk for nerve pain, and lung cancer patients seem to ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...